Table 2.
Direct costs (€)
| First quarter (Q1) | Following quarters (Qn) | |
|---|---|---|
| Methotrexate monotherapy | ||
| Methotrexate | 24.28 | 27.45 |
| Folic acid | 5.98 | 5.98 |
| Administration and screening | 44.56 | 44.56 |
| Total direct costs | 74.82 | 77.99 |
| O’Dell Triple Therapy | ||
| Methotrexate | 24.28 | 27.45 |
| Folic acid | 5.98 | 5.98 |
| Sulfasalazine | 93.67 | 93.67 |
| Hydroxychloroquine | 51.85 | 51.85 |
| Administration and screening | 44.56 | 44.56 |
| Total direct costs | 220.34 | 223.51 |
| Adalimumab combination therapy | ||
| Adalimumab | 5,666.78 | 5,666.78 |
| Methotrexate | 24.28 | 27.45 |
| Administration and screening | 252.20 | 63.49 |
| Total direct costs | 5,943.26 | 5,757.71 |